Hauptseite > Publikationsdatenbank > Surprisingly high stability of the Aβ oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs > print

001     836466
005     20210129231010.0
024 7 _ |a 10.1016/j.ejps.2017.07.015
|2 doi
024 7 _ |a WOS:000407836700020
|2 WOS
024 7 _ |a 2128/18656
|2 Handle
024 7 _ |a altmetric:22265612
|2 altmetric
024 7 _ |a pmid:28711713
|2 pmid
037 _ _ |a FZJ-2017-05584
082 _ _ |a 610
100 1 _ |a Elfgen, Anne
|0 P:(DE-Juel1)164354
|b 0
|u fzj
245 _ _ |a Surprisingly high stability of the Aβ oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs
260 _ _ |a New York, NY [u.a.]
|c 2017
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1527083281_26354
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The aggregation of the amyloid β protein (Aβ) plays an important role in the pathology of Alzheimer's disease. Previously, we have developed the all-d-enantiomeric peptide D3, which is able to eliminate neurotoxic Aβ oligomers in vitro and improve cognition in a transgenic Alzheimer's disease mouse model in vivo even after oral administration. d-Peptides are expected to be more resistant against enzymatic proteolysis compared to their l-enantiomeric equivalents, and indeed, a pharmacokinetic study with tritiated D3 revealed the oral bioavailability to be about 58%. To further investigate the underlying properties, we examined the stability of D3 in comparison to its corresponding all-l-enantiomeric mirror image l-D3 in media simulating the gastrointestinal tract, blood and liver. Potential metabolization was followed by reversed-phase high-performance liquid chromatography. In simulated gastric fluid, D3 remained almost completely stable (89%) within 24 h, while 70% of l-D3 was degraded within the same time period. Notably, in simulated intestinal fluid, D3 also remained stable (96%) for 24 h, whereas l-D3 was completely metabolized within seconds. In human plasma and human liver microsomes, l-D3 was metabolized several hundred times faster than D3. The remarkably high stability may explain the high oral bioavailability seen in previous studies allowing oral administration of the drug candidate. Thus, all-d-enantiomeric peptides may represent a promising new compound class for drug development.
536 _ _ |a 553 - Physical Basis of Diseases (POF3-553)
|0 G:(DE-HGF)POF3-553
|c POF3-553
|f POF III
|x 0
700 1 _ |a Santiago-Schübel, Beatrix
|0 P:(DE-Juel1)133853
|b 1
|u fzj
700 1 _ |a Gremer, Lothar
|0 P:(DE-Juel1)145165
|b 2
|u fzj
700 1 _ |a Kutzsche, Janine
|0 P:(DE-Juel1)159137
|b 3
|u fzj
700 1 _ |a Willbold, Dieter
|0 P:(DE-Juel1)132029
|b 4
|e Corresponding author
|u fzj
773 _ _ |a 10.1016/j.ejps.2017.07.015
|0 PERI:(DE-600)1483522-8
|p 203-207
|t European journal of pharmaceutical sciences
|v 107
|y 2017
|x 0928-0987
856 4 _ |u https://juser.fz-juelich.de/record/836466/files/1-s2.0-S0928098717304141-main.pdf
|y Restricted
856 4 _ |y Published on 2017-07-12. Available in OpenAccess from 2018-07-12.
|u https://juser.fz-juelich.de/record/836466/files/Elfgen%20et%20al.%202017.pdf
856 4 _ |y Published on 2017-07-12. Available in OpenAccess from 2018-07-12.
|x icon
|u https://juser.fz-juelich.de/record/836466/files/Elfgen%20et%20al.%202017.gif?subformat=icon
856 4 _ |y Published on 2017-07-12. Available in OpenAccess from 2018-07-12.
|x icon-1440
|u https://juser.fz-juelich.de/record/836466/files/Elfgen%20et%20al.%202017.jpg?subformat=icon-1440
856 4 _ |y Published on 2017-07-12. Available in OpenAccess from 2018-07-12.
|x icon-180
|u https://juser.fz-juelich.de/record/836466/files/Elfgen%20et%20al.%202017.jpg?subformat=icon-180
856 4 _ |y Published on 2017-07-12. Available in OpenAccess from 2018-07-12.
|x icon-640
|u https://juser.fz-juelich.de/record/836466/files/Elfgen%20et%20al.%202017.jpg?subformat=icon-640
856 4 _ |y Published on 2017-07-12. Available in OpenAccess from 2018-07-12.
|x pdfa
|u https://juser.fz-juelich.de/record/836466/files/Elfgen%20et%20al.%202017.pdf?subformat=pdfa
856 4 _ |x icon
|u https://juser.fz-juelich.de/record/836466/files/1-s2.0-S0928098717304141-main.gif?subformat=icon
|y Restricted
856 4 _ |x icon-1440
|u https://juser.fz-juelich.de/record/836466/files/1-s2.0-S0928098717304141-main.jpg?subformat=icon-1440
|y Restricted
856 4 _ |x icon-180
|u https://juser.fz-juelich.de/record/836466/files/1-s2.0-S0928098717304141-main.jpg?subformat=icon-180
|y Restricted
856 4 _ |x icon-640
|u https://juser.fz-juelich.de/record/836466/files/1-s2.0-S0928098717304141-main.jpg?subformat=icon-640
|y Restricted
856 4 _ |x pdfa
|u https://juser.fz-juelich.de/record/836466/files/1-s2.0-S0928098717304141-main.pdf?subformat=pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:836466
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)164354
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)133853
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)145165
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)159137
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)132029
913 1 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-553
|2 G:(DE-HGF)POF3-500
|v Physical Basis of Diseases
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Embargoed OpenAccess
|0 StatID:(DE-HGF)0530
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J PHARM SCI : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 0
920 1 _ |0 I:(DE-Juel1)ZEA-3-20090406
|k ZEA-3
|l Analytik
|x 1
980 1 _ |a FullTexts
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
980 _ _ |a I:(DE-Juel1)ZEA-3-20090406
981 _ _ |a I:(DE-Juel1)IBI-7-20200312

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21